New York, NY -- (SBWIRE) -- 12/06/2013 -- PennyStockChronicle covers the breadth of the markets, from NASDAQ, NYSE, AMEX, ETF, Penny Stocks, Emerging Markets, activities at the Fed and more. PennyStockChronicle brings you the most vibrant coverage of following stocks: All Grade Mining Inc (OTCMKTS:HYII), Arca Biopharma Inc (NASDAQ:ABIO), Geron Corporation (NASDAQ:GERN), Exxon Mobil Corporation (NYSE:XOM)
All Grade Mining Inc (OTCMKTS:HYII) showed a volume of 141.74 million shares by the end of last trade whereas the average volume of the stock remained 1.37million shares. At that price, the stock showed a positive performance of 120.00%. All Grade Mining, Inc. is a development-stage company. The Company is engaged in the acquisition and exploration of mining properties. The Saltirosa mine, which the Company has a deposit on, is located in the country of Chile approximately 28 kilometers from Chanaral and 60 kilometers from the Caldera port. As of December 31, 2012, the Company had no revenue.
Will HYII Continue To Move Higher? Find Out Here
Arca Biopharma Inc (NASDAQ:ABIO) opened the session at $1.78 and closed the session at $1.65. The stock showed a negative performance of -8.33% in previous trading session. Traded with volume of 3.23 million shares in the prior session and the average volume of the stock remained 1.41 million shares. ARCA biopharma, Inc. (ARCA) is a biopharmaceutical company. The Company's principal focus is developing genetically-targeted therapies for heart failure and other cardiovascular diseases. ARCA's lead product candidate is Gencaro TM (bucindolol hydrochloride), a pharmacologically beta-blocker and mild vasodilator being developed for the treatment of chronic heart failure (HF). The Company has collaborated with LabCorp to develop the Gencaro Test,
Has ABIO Found The Bottom And Ready To Gain Momentum? Find Out Here
Geron Corporation (NASDAQ:GERN) opened the session at $5.86 and closed the session at $5.87. The stock showed a positive performance of 2.26% in previous trading session. Traded with volume of 7.26 million shares in the prior session and the average volume of the stock remained 5.95 million shares. The beta of the stock remained 1.24. Geron Corporation (Geron) is a clinical-stage biopharmaceutical company developing a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. Telomerase is an enzyme that enables cancer cells to maintain telomere length, which provides them with the capacity for limitless cellular replication.
Why Should Investors Buy GERN After The Recent Gain? Just Go Here and Find Out
Exxon Mobil Corporation (NYSE:XOM) the stock decreased -0.57% and finished the session at $94.13. Traded with volume of 10.59 million shares in the prior session and the average volume of the stock remained 12.48 million shares. The beta of the stock remained 0.67. Exxon Mobil Corporation (Exxon Mobil) is a manufacturer and marketer of commodity petrochemicals, including olefins, aromatics, polyethylene and polypropylene plastics and a range of specialty products. The Company has a number of divisions and affiliates with names that include ExxonMobil, Exxon, Esso or Mobil. Divisions and affiliated companies of ExxonMobil operate or market products in the United States and other countries of the world.
Will XOM Get Buyers Even After The Recent Rally? Find Out Here
Penny Stock Chronicle is comprised of a team of vetted penny stock traders who’ve been trading since 2008 & have developed the skills needed to trade for consistent profits.
PLEASE NOTE WELL: The employees of PennyStockChronicle.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Verify all claims and do your own due diligence on all securities. PennyStockChronicle.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyStockChronicle.com is not offering securities for sale. Neither PennyStockChronicle.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by PennyStockChronicle.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. PennyStockChronicle.com does not recommend that the securities profiled should be purchased, sold or held.
Read Full Disclaimer at: http://pennystockchronicle.com/disclaimer
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)